title: Multiple sclerosis treatment: risk mitigation.
abstract: The growing number of disease-modifying medications approved for multiple sclerosis (MS) treatment is a significant step forward and provides new options for our patients. These medications, however, have differing efficacy and risk profiles. Although accurate predictors of efficacy are not available, treatment choices can be guided by patient-specific risk stratification. The use of risk mitigation strategies can help clinicians tailor MS treatment recommendations for individual patients.
authors.affiliation: Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. ontaned@ccf.org
authors.forename: Daniel
authors.initials: D
authors.lastname: Ontaneda
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Fox
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D002491:Central Nervous System Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D057285:Precision Medicine; D018570:Risk Assessment / Q000379:methods
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D002491:Central Nervous System Agents; D000069442:Natalizumab